Butyrate reduced ALS-linked protein clumps and improved movement in worms and cells
Original source
The HDAC Inhibitor Butyrate Reduces SOD1 Aggregation and Improves Motor Function in C. elegans and Cellular Models of ALS. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Population inferred from the title and abstract by Compass.
Related topics
In laboratory models of ALS, sodium butyrate reduced clumps of mutated SOD1 protein. It also improved movement and nerve-cell structure in genetically modified worms, and prevented SOD1 clumping in human neuroblastoma cells. The findings point to histone deacetylase inhibition as a possible mechanism for further study.
Why this matters
The results identify a potential route for studying SOD1-related ALS and support the use of worms and cultured cells to investigate it. They are early laboratory findings and do not show that butyrate or other histone deacetylase inhibitors improve ALS in people or should change treatment.
Limitations and context
This was preclinical research in genetically modified worms and cultured cells, not a human clinical study. The findings need to be tested in further disease models and clinical trials before any treatment implications can be established.